Novocure (NSDQ:NVCR) touted data today from the Phase III pivotal trial of its Optune device in combination with temozolomide for the treatment of newly-diagnosed glioblastoma.
The analyses were presented at the American Society for Radiation Oncology’s 2017 annual meeting in San Diego.
Get the full story at our sister site, Drug Delivery Business News.
The post ASTRO ’17 Round-up: Novocure touts five-year results for Optune, chemo combo in newly-diagnosed glioblastoma patients appeared first on MassDevice.